The U.S. Centers for Disease Control and Prevention (CDC) on March 29 updated its recommendation to allow certain immunocompromised individuals and people over the age of 50 to receive an additional booster dose of COVID-19 vaccines.
Moderna reported positive interim results from the Phase II/III KidCOVE trial of the company’s mRNA COVID-19 vaccine for children six months to under two years and also two to six years of age.
While Moderna and Pfizer-BioNTech have submitted Emergency Use Authorization (EUA) requests for their COVID-19 vaccines, the data so far suggest the benefits of a fourth shot may be modest.
Moderna Inc. on late March 17 sought emergency use authorization from U.S. health regulators for a second COVID-19 booster shot, as a surge in cases in some parts of the world fuels fears of another wave of the pandemic.
The World Health Organization (WHO) delayed its ongoing assessment of Russia’s Sputnik V coronavirus vaccine for emergency use because of Moscow’s invasion of Ukraine, an official from the health agency said on March 16.
Pfizer Inc. and the company’s German partner BioNTech SE on March 15 filed an application with U.S. regulators seeking emergency use authorization for a second booster shot of their COVID-19 vaccine for people aged 65 and older.
The U.S. Food and Drug Administration turned down Malvern, Pa.-based Ocugen’s Emergency Use Authorization (EUA) request for Covaxin in children ages 2 to 18 years. Covaxin is a Covid-19 vaccine the clinical-stage biopharmaceutical company is co-developing with India’s Bharat Biotech.
The U.S. Food and Drug Administration revised the emergency use authorization (EUA) for AstraZeneca’s Evusheld to a higher dose to be effective in the prevention of COVID-19.
The World Health Organization indicated WHO is tracking four Omicron subvariants: BA.1, BA.1.1, BA.2 and BA.3. BA.2 has a growth advantage over BA.1, the variant responsible for the recent Omicron surge.
The U.S. Food and Drug Administration on February 11 authorized Eli Lilly and Co.’s COVID-19 antibody drug for people aged 12 and older at risk of severe illness, adding a tool that has been found to work against the highly contagious Omicron variant.
